Can moxa help protect us from COVID-19?
SARS Cov-2 ... COVID-19 ... nCoV19… whatever it’s called, can we help protect ourselves from it with moxa? - How dangerous is it, for...
‘Combatte Kudasai!’
Last week a friend and long-time supporter sent us a significant donation with this curious tag ‘combatte kudasai’.
The Good, the Bad … and the Significantly Absent A review of the 2019 Global TB Report
This year’s Global Report on TB was published last week by the WHO. It’s become a custom for us to comment on it on each occasion. First...
Extra-pulmonary TB - and missing millions?
“Extrapulmonary TB represented 14% of the 6.4 million incident cases that were notified in 2017, ranging from 8% in the WHO Western Pacific...
Eight miles high – blue sky speculations on the possible origins of moxa
It’s about 500 miles from Pyongyang in North Korea to Beijing in China - at least it is if you fly as the crow does. North Korea’s Koryo...
Latent TB (Part 4) – acquired immunity and mixed infections
Let’s set the scene by starting with some much-needed good news. Protection from further infection afforded by a TB infection In the...
Latent TB (Part 3) – moxa therapy, viability in the invisibility?
So far we’ve looked at some of the complexities and uncertainties relating to these so-called ‘latent’ aspects of a pandemic plague of...
Latent MDR-TB (Part 2): the invisible within the invisible
In Part 1 we discussed the nature of latent TB (LTBI), and some of the current (and recurrent) deficiencies in treating it. In this part,...
Latent tuberculosis (part 1) - The Invisible Plague
In the last month two studies have been published which have focused our attentions on latent TB - not least because their contents have...
‘Hundreds of people who drank at country pub tested after gran dies of TB’
We came across this headline last week in the UK national newspaper the Daily Mirror.[i] Naturally it drew our attention, and (along with...
